A Phase I Study of ALKS 4230 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs ALKS 4230 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Alkermes plc
- 08 Nov 2017 According to an Alkermes media release, the dose-escalation stage of this trial is ongoing and the dose expansion stage will be initiated in 2018.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 25 May 2016 According to an Alkermes plc media release, initial results from the first stage of the phase I study are expected in 2017.